Alector Inc.

Clinical-stage immuno-neurology biotech developing therapies for neurodegenerative diseases, built around its proprietary Alector Brain Carrier (ABC) blood-brain barrier delivery platform. Lead asset is nivisnebart (AL101/GSK4527226), a progranulin-elevating antibody partnered with GSK in Phase 2 PROGRESS-AD for early Alzheimer's disease, with a wholly-owned ABC-enabled pipeline spanning anti-amyloid antibodies, an engineered GCase enzyme, and tau/α-synuclein/NLRP3 siRNAs.